Moderna Developing Booster Shot for New Virus Variant B.1.351

New data suggest that the company’s approved COVID-19 vaccine protects against different virus variants, but could be less effective against the one that originated in South Africa.

asher jones
| 2 min read
COVID-19, SARS-CoV-2, pandemic, coronavirus, virus, Moderna, vaccine, vaccination, B.1.1.7, B.1.351, 501Y.V2, immunity, antibodies

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM,
VGAJIC

Moderna announced today (January 25) plans for testing two different booster vaccines aimed at the SARS-CoV-2 variant B.1.351, also known as 501Y.V2, that emerged in South Africa and has now spread to numerous countries.

“The virus is changing its stripes, and we will change to make sure we can beat the virus where it’s going,” Stephen Hoge, the president of Moderna, tells The Washington Post.

A study from Moderna posted to the preprint server bioRxiv today that has not yet been peer-reviewed reports that its vaccine produced neutralizing antibodies against several SARS-CoV-2 variants, including B.1.351 and B.1.1.7, the latter of which was first spotted in the UK and is rapidly becoming common in other countries. But antibody levels produced in response to B.1.351 were about six times lower than prior variants. Moderna’s statement says that these antibody titers “remain above levels that are expected to be protective,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • asher jones

    Asher Jones

    Asher is a former editorial intern at The Scientist. She completed a PhD in entomology from Penn State University, and she was a 2020 AAAS Mass Media Fellow at Voice of America. You can find more of her work here.

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide